Central Pharmaceutical Joint Stock Company No3 (HNX:DP3)

HNX:DP3 Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	405,733	417,485	409,731	485,074	381,077	395,721
Revenue Growth (YoY)	3.06%	1.89%	-15.53%	27.29%	-3.70%	-3.82%
Cost of Revenue	139,539	141,432	128,228	148,536	117,447	122,006
Gross Profit	266,194	276,054	281,503	336,538	263,630	273,715
Selling, General & Admin	127,187	139,372	144,618	208,717	151,491	140,383
Operating Expenses	127,187	139,372	144,618	208,717	151,491	140,383
Operating Income	139,007	136,682	136,885	127,821	112,139	133,332
Interest Expense	-141.56	-161.5	-1,594	-6,475	-449	-1,969
Interest & Investment Income	15,638	15,463	21,665	10,732	7,360	12,006
Currency Exchange Gain (Loss)	-133.63	-133.63	-15.04	-	-	-
Other Non Operating Income (Expenses)	-334.22	-97.52	60.97	4,412	-839.85	-409.28
EBT Excluding Unusual Items	154,035	151,752	157,001	136,490	118,210	142,960
Gain (Loss) on Sale of Assets	163.2	163.2	2.28	-	-	-
Pretax Income	154,198	151,915	157,003	136,490	118,210	142,960
Income Tax Expense	31,204	30,743	31,740	27,665	23,905	28,899
Net Income	122,994	121,172	125,263	108,824	94,305	114,061
Net Income to Common	122,994	121,172	125,263	108,824	94,305	114,061
Net Income Growth	-0.06%	-3.27%	15.11%	15.40%	-17.32%	37.75%
Shares Outstanding (Basic)	21	21	21	23	21	21
Shares Outstanding (Diluted)	21	21	21	23	21	21
Shares Change (YoY)	1.32%	-	-5.00%	5.27%	-0.00%	-2.18%
EPS (Basic)	5720.99	5635.90	5826.22	4808.40	4386.40	5305.20
EPS (Diluted)	5720.99	5635.90	5826.22	4808.40	4386.40	5305.20
EPS Growth	-1.37%	-3.27%	21.17%	9.62%	-17.32%	40.81%
Free Cash Flow	122,270	90,452	146,699	84,126	25,862	54,119
Free Cash Flow Per Share	5687.32	4207.10	6823.21	3717.11	1202.91	2517.18
Dividend Per Share	-	-	3000.000	-	2400.000	-
Gross Margin	65.61%	66.12%	68.70%	69.38%	69.18%	69.17%
Operating Margin	34.26%	32.74%	33.41%	26.35%	29.43%	33.69%
Profit Margin	30.31%	29.02%	30.57%	22.43%	24.75%	28.82%
Free Cash Flow Margin	30.14%	21.67%	35.80%	17.34%	6.79%	13.68%
EBITDA	151,587	149,542	150,864	-	-	-
EBITDA Margin	37.36%	35.82%	36.82%	-	-	-
D&A For EBITDA	12,581	12,861	13,980	-	-	-
EBIT	139,007	136,682	136,885	127,821	112,139	133,332
EBIT Margin	34.26%	32.74%	33.41%	26.35%	29.43%	33.69%
Effective Tax Rate	20.24%	20.24%	20.22%	20.27%	20.22%	20.21%
Revenue as Reported	405,733	417,485	409,731	485,074	381,077	395,721

Source: S&P Global Market Intelligence. Standard template. Financial Sources.